A Phase 3 trial in Gabon presented at ASTMH found that a single‑dose regimen combining four existing antimalarials matched the effectiveness of conventional multi‑day therapy. Investigators reported equivalent clinical outcomes in the trial population, offering a potential simplification of malaria treatment delivery in endemic settings. The study was presented to the American Society of Tropical Medicine and Hygiene and involved local clinical trial sites. If adopted, a single‑dose option could ease adherence and logistics where multi‑day regimens create barriers, though implementation will depend on safety, cost and supply considerations.